Related Experiment Video
Updated: Oct 11, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis
Masatake Kobayashi1, Maria Betânia Ferreira2,3,4, Rita Quelhas Costa5
1Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.
Insights
Biomarkers linked to inflammation, matrix remodeling, and injury correlate with cardiac changes in rheumatoid arthritis (RA) patients. These findings suggest potential for using biomarkers to screen for heart issues in RA.
Area of Science:
- Cardiology
- Rheumatology
- Biomarker Discovery
Background:
- Rheumatoid arthritis (RA) poses a significant risk for cardiac structural and functional abnormalities, potentially leading to heart failure (HF).
- Identifying patients with RA at higher risk for cardiac dysfunction necessitates studying associations between circulating biomarkers and echocardiographic parameters.
Purpose of the Study:
- To investigate the relationship between circulating biomarkers and echocardiographic parameters in patients diagnosed with rheumatoid arthritis.
- To assess the utility of these associations in predicting cardiovascular events.
Main Methods:
- Echocardiography was performed on 355 RA patients from the RA Porto cohort.
- Associations between echocardiographic measures and 94 circulating biomarkers were analyzed.
- External validation was conducted in heart failure with preserved ejection fraction (HFpEF) and healthy cohorts (MEDIA-DHF and STANISLAS).
Main Results:
- In RA patients, left ventricular mass index (LVMi), left atrial volume index (LAVi), and E/e' were independently linked to biomarkers of inflammation, extracellular matrix remodeling, congestion, and myocardial injury.
- Elevated LVMi, LAVi, and E/e' were associated with increased cardiovascular event rates.
- These associations were confirmed in HFpEF and healthy populations.
Conclusions:
- Circulating biomarkers reflecting inflammation, extracellular matrix remodeling, congestion, and myocardial injury are associated with cardiac structural and functional alterations in RA.
- These biomarkers may serve as a valuable tool for screening cardiac abnormalities in patients with rheumatoid arthritis.
Abstract:
Background: Rheumatoid arthritis (RA) increases the risk for abnormalities of the cardiac structure and function, which may lead to heart failure (HF). Studying the association between circulating biomarkers and echocardiographic parameters is important to screen patients with RA with a higher risk of cardiac dysfunction. Aim: To study the association between circulating biomarkers and echocardiographic parameters in patients with RA. Methods: Echocardiography was performed in 355 patients with RA from RA Porto cohort and the associations between echocardiographic characteristics and 94 circulating biomarkers were assessed. These associations were also assessed in the Metabolic Road to Diastolic Heart Failure (MEDIA-DHF) [392 patients with HF with preserved ejection fraction (HFpEF)] and the Suivi Temporaire Annuel Non-Invasif de la Santé des Lorrains Assurés Sociaux (STANISLAS) (1,672 healthy population) cohorts. Results: In the RA Porto cohort, mean age was 58 ± 13 years, 23% were males and mean RA duration was 12 ± 10 years. After adjustment and multiple testing correction, left ventricular mass index (LVMi), left atrial volume index (LAVi), and E/e' were independently associated with biomarkers reflecting inflammation [i.e., bone morphogenetic protein 9 (BMP9), pentraxin-related protein 3 (PTX3), tumor necrosis factor receptor superfamily member 11a (TNFRSF11A)], extracellular matrix remodeling [i.e., placental growth factor (PGF)], congestion [i.e., N-terminal pro-brain natriuretic peptide (NT-proBNP), adrenomedullin (ADM)], and myocardial injury (e.g., troponin). Greater LVMi [hazard ratio (HR) (95% CI) per 1 g/m2 = 1.03 (1.02-1.04), p < 0.001], LAVi [HR (95% CI) per 1 ml/m2 = 1.03 (1.01-1.06), p < 0.001], and E/e' [HR (95% CI) per 1 = 1.08 (1.04-1.13), p < 0.001] were associated with higher rates of cardiovascular events. These associations were externally replicated in patients with HFpEF and asymptomatic individuals. Conclusion: Circulating biomarkers reflecting inflammation, extracellular matrix remodeling, congestion, and myocardial injury were associated with underlying alterations of cardiac structure and function. Biomarkers might be used for the screening of cardiac alterations in patients with RA.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Rheumatic Heart Disease I: Introduction
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Rheumatic Heart Disease IV: Nursing Management
Cardiomyopathy IV: Restrictive Cardiomyopathy

